Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: A randomized pilot study

American Journal of Gastroenterology

Volumn 103, Issue 6, 2008, Pages 1399-1405

  Singh, Virendra ^a   Dheerendra, Prashant C ^a   Singh, Baljinder ^a   Nain, Chander K ^a   Chawla, Divya ^a   Sharma, Navneet ^a   Bhalla, Ashish ^a   Mahi, Sushil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; MIDODRINE; RENIN; SODIUM;

ADULT; ARTERIAL PRESSURE; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER ISCHEMIA; MALE; PARACENTESIS; PILOT STUDY; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; TREATMENT OUTCOME;

ADULT; ASCITES; FEMALE; HUMANS; HYPOVOLEMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIDODRINE; PARACENTESIS; PILOT PROJECTS; SERUM ALBUMIN; TREATMENT OUTCOME; VASOCONSTRICTOR AGENTS;

EID: 44949240317     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2008.01787.x     Document Type: Article

References (21)

1. Ruiz-Del-Arbol L, Monescillo A, Jimenez W, et al. Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997 113 : 579 86.
2. Pozzi M, Osculati G, Boari G, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense refractory ascites. Gastroenterology 1994 106 : 709 19.
3. Simon DM, McCain JR, Bonkovsky HL, et al. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 1987 7 : 423 9.
4. Gines P, Tito LI, Arroyo V, et al. Randomised comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988 94 : 1493 502.
5. Garcia-Compean D, Villareal JZ, Cuevas HB, et al. Total therapeutic paracentesis (TTP) with and without intravenous albumin in the treatment of cirrhotic tense ascites: A randomized controlled trial. Liver 1993 13 : 233 8.
6. Gines A, Fernandez- Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, Dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996 111 : 1002 10.
7. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhosis with ascites. Hepatology 2003 37 : 1147 53.
8. Luca A, Garcia-Pagan JC, Bosch J, et al. Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. Hepatology 1995 22 : 753 8.
9. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998 27 : 264 72.
10. Runyon BA. Albumin infusion for spontaneous bacterial peritonitis. Lancet 1999 354 : 1838 9.
11. Schrier RW, Arroyo V, Bernardi M, et al. Peripheral arteriolar vasodilatation hypothesis: A proposal for initiation of renal sodium and water retention in cirrhosis. Hepatology 1988 8 : 1151 7.
12. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: Pathophysiological basis of therapy and current management. J Hepatol 2003 38 (Suppl 1 69 89.
13. Vila MC, Sola R, Molina L, et al. Hemodynamic changes in patients developing effective hypovolemia after total paracentesis. J Hepatol 1998 28 : 639 45.
14. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: A randomised pilot study. Gut 2002 50 : 90 4.
15. Singh V, Kumar R, Nain CK, et al. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: A randomized controlled trial. J Gastroenterol Hepatol 2006 21 : 303 7.
16. Singh V, Kumar B, Nain CK, et al. Noradrenaline and albumin in paracentesis-induced circulatory dysfunction in cirrhosis: A randomized pilot study. J Intern Med 2006 260 : 62 8.
17. McTavish D, Goa KL. Midodrine: A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989 38 : 757 77.
18. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999 29 : 1690 7.
19. Kalambokis G, Fotopoulos A, Economou M, et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients without and with ascites. J Hepatol 2007 46 : 213 21.
20. Arroyo V, Jimenez W. Complications of cirrhosis. II. Renal and circulatory dysfunction. Lights and shadows in an important clinical problem. J Hepatol 2000 32 (Suppl 1 157 70.
21. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998 28 : 937 43.